Elevated plasma concentrations of cFGF23 and iFGF23 are found from early stages of renal impairment followed by an increase in plasma phosphate and PTH as CKD progresses.(42, 51) This is associated with soft tissue calcification and increased risk of cardiovascular disease (CVD).(52) It is also associated with low plasma concentrations of 1,25(OH)2D due to the aforementioned FGF23‐mediated inhibition of production and increased catabolism. The gene discussed is FGF23; the disease is chronic kidney disease.